ITGR:NYE-Integer Holdings Corp (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 137.56

Change

+0.67 (+0.49)%

Market Cap

USD 4.59B

Volume

0.32M

Analyst Target

USD 100.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was formerly known as Greatbatch, Inc. and changed its name to Integer Holdings Corporation in July 2016. The company was founded in 1970 and is headquartered in Plano, T

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

-0.70 (-0.60%)

USD 201.96B
MDT Medtronic PLC

-0.33 (-0.37%)

USD 115.52B
STE STERIS plc

-0.46 (-0.21%)

USD 21.88B
ZBH Zimmer Biomet Holdings Inc

+0.03 (+0.03%)

USD 21.28B
GMED Globus Medical

-0.88 (-1.05%)

USD 11.01B
SNN Smith & Nephew SNATS Inc

+0.04 (+0.16%)

USD 10.91B
BIO Bio-Rad Laboratories Inc

-1.33 (-0.36%)

USD 10.06B
PEN Penumbra Inc

-0.17 (-0.07%)

USD 9.07B
GKOS Glaukos Corp

-0.38 (-0.26%)

USD 7.82B
INSP Inspire Medical Systems Inc

-8.57 (-4.49%)

USD 6.34B

ETFs Containing ITGR

PSCH Invesco S&P SmallCap Heal.. 0.00 % 0.29 %

-0.51 (0%)

USD 0.18B
JELS:LSE 0.00 % 0.00 %

N/A

N/A
JLES:LSE 0.00 % 0.00 %

N/A

N/A
JLSP:LSE 0.00 % 0.00 %

N/A

N/A
JPQE:F 0.00 % 0.00 %

N/A

N/A
JPQE:XETRA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 38.84% 77% C+ 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.84% 77% C+ 89% A-
Trailing 12 Months  
Capital Gain 55.26% 77% C+ 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 55.26% 77% C+ 89% A-
Trailing 5 Years  
Capital Gain 84.00% 74% C 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 84.00% 74% C 78% C+
Average Annual (5 Year Horizon)  
Capital Gain 15.24% 77% C+ 76% C+
Dividend Return 15.24% 77% C+ 73% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.42% 70% C- 38% F
Risk Adjusted Return 53.64% 87% B+ 70% C-
Market Capitalization 4.59B 62% D 76% C+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector